ECSP993016A - THERAPEUTIC COMBINATIONS INCLUDING A SELECTIVE ESTROGEN RECEPTOR AND PARATOROID HORMONE MODULATOR - Google Patents

THERAPEUTIC COMBINATIONS INCLUDING A SELECTIVE ESTROGEN RECEPTOR AND PARATOROID HORMONE MODULATOR

Info

Publication number
ECSP993016A
ECSP993016A ECSP993016A ECSP993016A EC SP993016 A ECSP993016 A EC SP993016A EC SP993016 A ECSP993016 A EC SP993016A EC SP993016 A ECSP993016 A EC SP993016A
Authority
EC
Ecuador
Prior art keywords
paratoroid
compositions
estrogen receptor
selective estrogen
combinations including
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Hua Zhu Ke
David Duane Thompson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to ECSP993016 priority Critical patent/ECSP993016A/en
Publication of ECSP993016A publication Critical patent/ECSP993016A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención se refiere a composiciones farmacéuticas de combinación y a procedimientos que comprenden (-) -cis-6-fenil-5-(4-(2-pirrolidin-1-il-etoxi)-fenil-5,6,7,8-tetrahidronaftalen-2-ol, o una de sus sales farmacéuticamente aceptables y hormona paratoroidea, o uno de sus fragmentos biológicamente activos, a procedimientos para usar dichas composiciones y a estuches que contienen dichas composiciones. Las composiciones son útiles para tratar fragilidad musculoesquelética, incluyendo osteoporosis, fractura osteoporótica, masa ósea reducida y fragilidad.This invention relates to combination pharmaceutical compositions and processes comprising (-) -cis-6-phenyl-5- (4- (2-pyrrolidin-1-yl-ethoxy) -phenyl-5,6,7,8- tetrahydronaphthalen-2-ol, or one of its pharmaceutically acceptable salts and paratoroid hormone, or one of its biologically active fragments, to procedures for using said compositions and to kits containing said compositions.The compositions are useful for treating musculoskeletal fragility, including osteoporosis, osteoporotic fracture, reduced bone mass and fragility.

ECSP993016 1999-06-15 1999-06-15 THERAPEUTIC COMBINATIONS INCLUDING A SELECTIVE ESTROGEN RECEPTOR AND PARATOROID HORMONE MODULATOR ECSP993016A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP993016 ECSP993016A (en) 1999-06-15 1999-06-15 THERAPEUTIC COMBINATIONS INCLUDING A SELECTIVE ESTROGEN RECEPTOR AND PARATOROID HORMONE MODULATOR

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP993016 ECSP993016A (en) 1999-06-15 1999-06-15 THERAPEUTIC COMBINATIONS INCLUDING A SELECTIVE ESTROGEN RECEPTOR AND PARATOROID HORMONE MODULATOR

Publications (1)

Publication Number Publication Date
ECSP993016A true ECSP993016A (en) 1999-08-12

Family

ID=42044005

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP993016 ECSP993016A (en) 1999-06-15 1999-06-15 THERAPEUTIC COMBINATIONS INCLUDING A SELECTIVE ESTROGEN RECEPTOR AND PARATOROID HORMONE MODULATOR

Country Status (1)

Country Link
EC (1) ECSP993016A (en)

Similar Documents

Publication Publication Date Title
IS2132B (en) Use of estrogen for the manufacture of a medicinal product for the treatment of menopause
ECSP055738A (en) ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF BOTH ENANTIOMERS OF 10,11-DIHIDRO-10-HIDROXI-5H-DIBENZ- [b, f] -AZEPIN-5-CARBOXAMIDE AND ITS NEW GLASS FORMS
TR200000927T2 (en) Treatment of prostaglandin agonists and bone disorders
AR005987A1 (en) COMBINED THERAPY FOR OSTEOPOROSIS
BR9714155A (en) Prevention of bone mass loss and replacement by certain prostaglandin agonists.
AP9801269A0 (en) Prostaglandin agonists.
ATE438618T1 (en) INHIBITORS OF HUMAN ADAM-10
PA8471201A1 (en) THERAPEUTIC COMBINATIONS INCLUDING A SELECTIVE STROGEN RECEPTOR AND PARATHYROID HORMONE MODULATOR
DK1420827T3 (en) 5-CNAC sp, oral administration agent for parathyroid hormone fragments
CY1117666T1 (en) 4 - ((FAOXYLYL) SULFUR) -PHEOXIC ACIDS FOR USE IN THERAPEUTIC MEDICINE PURPOSES
ID18079A (en) PHARMACEUTICAL COMPOSITION THAT CONTAINS FASTEST OSTEOGENESIS
DK1525215T3 (en) Modulators for the progesterone receptor with elevated anti-gonadotropic activity for women's fertility control and hormone replacement therapy
ECSP993016A (en) THERAPEUTIC COMBINATIONS INCLUDING A SELECTIVE ESTROGEN RECEPTOR AND PARATOROID HORMONE MODULATOR
PA8475901A1 (en) COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY
NO20006381L (en) Therapeutic combinations of (selective) estrogen receptor modulators (SERM) and growth hormone secretion agents
DE69916932D1 (en) Combination therapeutic agents containing a selective estrogen receptor modulator and prostaglandin E2
ECSP993020A (en) COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY
IT1307866B1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING INHIBITORS OF GROWTH HORMONE OR THEIR BIOLOGICALLY ACTIVE FRAGMENTS FOR TREATMENT
UY26651A1 (en) COMBINED THERAPY FOR OSTEOPOROSIS
ECSP993021A (en) THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY
UA28851A (en) Method of operative treatment of the tibia distal epiphysis fructures